{"id":"NCT03894046","sponsor":"Entasis Therapeutics","briefTitle":"Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex","officialTitle":"A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-05","primaryCompletion":"2021-07-26","completion":"2021-07-26","firstPosted":"2019-03-28","resultsPosted":"2023-02-01","lastUpdate":"2023-02-01"},"enrollment":207,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acinetobacter Baumannii-calcoaceticus Complex","Hospital-acquired Bacterial Pneumonia","Ventilator-associated Bacterial Pneumonia","Bacteremia","Colistin Resistant ABC"],"interventions":[{"type":"DRUG","name":"Sulbactam","otherNames":[]},{"type":"DRUG","name":"Durlobactam","otherNames":["ETX2514"]},{"type":"DRUG","name":"Colistin","otherNames":["COLOMYCIN INJECTION 2 million IU/vial"]},{"type":"DRUG","name":"Imipenem/Cilastatin 500 mg/500 mg","otherNames":[]}],"arms":[{"label":"Part A - Group 1","type":"EXPERIMENTAL"},{"label":"Part A - Group 2","type":"ACTIVE_COMPARATOR"},{"label":"Part B - Group 3","type":"EXPERIMENTAL"}],"summary":"This is a 2-part study, with Part A being the randomized, controlled portion of the study in patients with ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or bacteremia. Part B is the single-group portion of the study and includes ABC infections that are resistant to or have failed colistin or polymyxin B treatment, as detailed in the inclusion criteria.","primaryOutcome":{"measure":"Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population","timeFrame":"28 Days","effectByArm":[{"arm":"Part A - Group 1","deltaMin":12,"sd":null},{"arm":"Part A - Group 2","deltaMin":20,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":90,"countries":["United States","Belarus","Brazil","China","Greece","Hungary","India","Israel","Lithuania","Mexico","Peru","Puerto Rico","Russia","South Korea","Taiwan","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["37182534"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":91},"commonTop":["Anaemia","Diarrhoea","Hypokalaemia","Pyrexia","Urinary tract infection"]}}